In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Nestle Health Science gets ex-US and Canadian rights to Seres' CDI and IBD compounds

Executive Summary

Seres Therapeutics Inc. licensed Nestle Health Science SA exclusive rights to develop and commercialize outside the US and Canada candidates aimed at Clostridium difficile infection (Phase II SER109 and preclinical SER262) and inflammatory bowel disease, including ulcerative colitis (Phase I SER287) and Crohn’s (SER301--unknown phase).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies